Oleg Nodelman

Oleg Nodelman is the Founder and Portfolio Manager of EcoR1 Capital LLC, a biotech-focused investment advisory firm established in 2013, which invests in companies at all stages of research and development. With over twenty years of experience in biotech investing, Mr. Nodelman has expertise in all aspects of investment management and deep roots in the biotech and scientific communities. Before founding EcoR1, Mr. Nodelman was a portfolio manager at BVF Partners, one of the first hedge funds dedicated to investing in the biotechnology sector. He currently serves as a Board Member for three publicly traded companies: AnaptysBio (NASDAQ: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics applicable to inflammatory and autoimmune diseases, Galapagos (Euronext & NASDAQ: GLPG), a clinical-stage biotechnology company focused on small molecules, CAR-T therapies, and biologics in oncology and immunology, and Zymeworks (NASDAQ: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease. Mr. Nodelman has a Bachelor of Science in Foreign Service with a concentration in Science and Technology from Georgetown University.